NASDAQ:MPLT Maplight Therapeutics Q3 2025 Earnings Results & Report $8.83 -0.32 (-3.50%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$8.85 +0.02 (+0.17%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Maplight Therapeutics missed analyst earnings expectations in its Q3 2025 results, released December 4, 2025. The company reported EPS of -$37.18 versus the -$1.86 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateDecember 4, 2025TimeBefore Market OpensConference Call7:00 AM ET Maplight Therapeutics EPS ResultsActual EPS-$37.18Consensus EPS -$1.86Beat/MissMissed by -$35.32One Year Ago EPSN/AEPS Beat Rate1 of last 4 quartersMaplight Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K) Maplight Therapeutics Q3 2025 Earnings FAQ Did Maplight Therapeutics beat earnings estimates for Q3 2025? Maplight Therapeutics (NASDAQ:MPLT) reported earnings of -$37.18 per share for Q3 2025, missing the consensus estimate of -$1.86. The report was announced on Thursday, December 4, 2025. Maplight Therapeutics Earnings HeadlinesMapLight co-founder is joint winner of 2026 Nobel Prize in MedicineOctober 6, 2026 | seekingalpha.comMapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of OptogeneticsOctober 6, 2026 | globenewswire.comNo. 1 stock to cash in on the death of iPhoneAnalyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now. | Stansberry Research (Ad)Maplight Therapeutics (NASDAQ:MPLT) Shares Down 5.5% - Should You Sell?October 5, 2026 | americanbankingnews.comMaplight Therapeutics (NASDAQ:MPLT) Cut to "Strong Sell" at Wall Street ZenOctober 3, 2026 | americanbankingnews.comMapLight Therapeutics, Inc.(NasdaqGS:MPLT) dropped from S&P Biotechnology Select Industry IndexSeptember 20, 2026 | marketscreener.comMSee More Maplight Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Maplight Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maplight Therapeutics and other key companies, straight to your email. Email Address About Maplight TherapeuticsMaplight Therapeutics (NASDAQ:MPLT) is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric and neurological disorders. The company focuses on conditions for which existing treatments may provide limited benefits or cause significant side effects. MapLight uses a neuroscience-focused drug discovery and development approach to identify therapies intended to address the underlying biology of central nervous system disorders. Its pipeline includes investigational small-molecule treatments being studied for conditions such as schizophrenia and other serious mental health disorders. The company conducts research and clinical development in the United States. Additional information about its commercial products, geographic operations and leadership is limited because MapLight Therapeutics remains primarily focused on advancing its investigational pipeline.View Maplight Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
